Abstract
Systemic lupus erythematosus (SLE) is a complex autoimmune disease influenced by both genetic and environmental factors. The GRB2 gene product is a critical factor in B-cell activation and has previously been associated with SLE in European populations. This study aimed to investigate this relationship in a Han Chinese population. By genotyping 20 tagging SNPs in 1,710 Han Chinese women (567 patients and 1,143 controls), we identified a significant association between SNP rs36023980 and SLE risk. The 'T' allele of rs36023980 was found to be protective (OR = 0.61, P = 0.0003). Furthermore, this SNP was linked to complement inhibition in patients and regulated GRB2 expression in whole blood and skin tissues. These findings confirm the role of GRB2 in SLE susceptibility across different ethnic groups.
Introduction
Systemic Lupus Erythematosus (SLE) is characterized by the production of autoantibodies and multi-organ inflammation. While Genome-Wide Association Studies (GWAS) have identified numerous risk loci, the genetic architecture of SLE varies significantly between ethnicities. The GRB2 (Growth Factor Receptor-Bound Protein 2) gene is a key signaling adapter involved in B-cell receptor signaling. Given its role in immune regulation and previous associations in European cohorts, validating its impact in the Han Chinese population—who often experience higher disease prevalence—is a critical step in understanding the global genetic landscape of SLE.
Methods and SNP Selection
The study cohort consisted of 1,710 unrelated Han Chinese women recruited from the Second Affiliated Hospital of Xi’an Jiaotong University. To capture the genetic variation of the GRB2 gene, 20 tagging SNPs were selected based on the 1000-Genomes CHB database. Genotyping was performed using the Sequenom MassARRAY platform.
Statistical analyses utilized logistic regression to assess associations, adjusting for age. Additionally, expression quantitative trait loci (eQTL) data from the GTEx database were analyzed to determine the functional impact of significant SNPs on gene expression across various human tissues.
Results
Identification of a Protective Variant
The primary finding of the study was the significant association of SNP rs36023980 with SLE. Both genotypic and allelic tests demonstrated that the 'T' allele serves as a protective factor against the development of the disease. Specifically, the frequency of the T allele was 6.3% in SLE patients compared to 10.2% in healthy controls, resulting in an odds ratio (OR) of 0.61 (P = 0.0003).
Clinical and Functional Correlations
Beyond overall risk, the rs36023980 genotype was significantly associated with complement inhibition ($P = 0.003$) in SLE patients. Stratification analysis revealed that the genetic signal was predominantly driven by the subgroup of patients exhibiting complement depression, suggesting that GRB2 may influence the innate immune system's clearance pathways.
Functional eQTL analysis further supported these findings. The risk-associated 'C' allele was correlated with higher expression levels of GRB2 in whole blood ($P = 7.7 \times 10^{-6}$) and sun-exposed skin ($P = 0.0003$). This suggests that increased production of the GRB2 protein may contribute to the hyper-activation of B cells and the subsequent autoimmune response characteristic of SLE.
Discussion and Conclusion
This study successfully validates the GRB2 locus as a susceptibility factor for SLE in the Han Chinese population, mirroring results found in European studies. The identification of rs36023980 as a regulatory variant affecting both gene expression and clinical manifestations like complement inhibition provides a biological bridge between genetic variation and disease pathology.
While the study is limited by its focus on female participants and intronic SNPs, it underscores the importance of GRB2 in the systemic and cutaneous manifestations of lupus. Future research should focus on the exact molecular mechanisms by which these non-coding variants modulate GRB2 expression and explore the potential of this pathway for targeted therapeutic interventions.
Summary updated